RPS6KB1

Across TCGA pan-cancer cohorts, RPS6KB1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPS6KB1 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RPS6KB1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPS6KB1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where RPS6KB1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.673	0.886	.020	8	view →
LUAD	DFS	Median	All	1.000	0.891	.014	4	view →
LSCC	OS	Quartile	III,IV	0.408	0.839	.007	3	view →
GBM	OS	Tertile	All	0.516	0.341	.035	2	view →
HNSC	DFS	Quartile	III,IV	0.378	1.000	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPS6KB1–PDAC (DFS)

Open the PDAC breakdown →